47 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
of the investment community;
The potential or actual gain or loss of a significant customer, supplier, or purchase order;
Joint ventures and distribution
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, adoption by the medical community of our product candidates, if approved, may be limited if third-party payors offer inadequate reimbursement … of our current product candidates by patients, the medical community, and third-party payors; our ability to compete with other therapies to treat OI
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
want to acknowledge the OI community and especially thank the people living with OI and their caregivers who have aided the setrusumab development
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
product candidates;
acceptance of any of our product candidates, if approved, by patients, the medical community and payors at our desired pricing
6-K
EX-99.2
a6xerfmc4zwqvl
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
9gvum5vun sfkm
26 May 22
Current report (foreign)
5:11pm
6-K
EX-99.2
adtfv5v
2 Nov 21
Current report (foreign)
4:16pm
F-3
EX-4.4
jewgy iiy
5 Aug 21
Shelf registration (foreign)
4:33pm
424B5
u0m1rdk0
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
sos141
9 Feb 21
Prospectus supplement for primary offering
5:24pm
6-K
EX-99.1
cbh6gn382 1sjw
17 Dec 20
Mereo BioPharma and Ultragenyx Announce Collaboration and License
5:16pm
424B5
ufpl v50lx81ft5hkk
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
3v6krb30
6 Oct 20
Shelf registration (foreign)
4:25pm